Compare Novartis AG (NVS) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs ProShares UltraPro Short QQQ ETF — how do they compare? Novartis AG trades at $143.81 (market cap $268.57B), while ProShares UltraPro Short QQQ ETF trades at $33.16 (market cap $2.23B). The key difference: Novartis AG is far larger — about 120.4× ProShares UltraPro Short QQQ ETF's market cap, and Novartis AG pays a 3.31% dividend while ProShares UltraPro Short QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| NVS | SQQQ | |
|---|---|---|
Market Cap | $268.57B | $2.23B |
Volume | 1,532,573 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $168.62 | $89.43 |
52-Week Low | $121.80 | $31.83 |
Typical Hold Time | 82 Days | 12 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
SQQQ (ProShares UltraPro Short QQQ) trades at $33.20, up 3.49% today, reflecting bearish market sentiment toward the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages heavily weighted toward selling pressure. The ETF is designed to deliver triple the inverse daily performance of the Nasdaq 100, making it a tactical tool for hedging or speculating on tech sector declines.
SQQQ's outlook remains tied to Nasdaq 100 volatility, with potential gains during market downturns but significant decay risk in flat or rising markets. Investors should consider the high-risk, leveraged nature of this instrument and its suitability primarily for short-term hedging strategies rather than long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
